Search results
Results from the WOW.Com Content Network
Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, used for the treatment of multiple sclerosis. [4] Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. It has been reported to reduce the rate of ...
A few medications have been studied to treat MS-related fatigue, such as amantadine [145] [146] pemoline (which is a psychostimulant also used for attention-deficit hyperactivity disorder and narcolepsy), [147] [148] or modafinil, [149] [150] [151] as well as psychological interventions of energy conservation, [152] [153] but the effects of all ...
Siponimod is indicated for the treatment of secondary progressive multiple sclerosis, which is the progressive neurological decline of multiple sclerosis that happens independent of acute relapses. [1] In active secondary progressive multiple sclerosis, siponimod decreases the risk of disability and multiple sclerosis relapses. [1]
Oral rehydration therapy (ORT) is a type of fluid replacement used to prevent and treat dehydration, especially due to diarrhea. [1] It involves drinking water with modest amounts of sugar and salts, specifically sodium and potassium. [1] Oral rehydration therapy can also be given by a nasogastric tube. [1]
Teriflunomide inhibits rapidly dividing cells, including activated T cells, which are thought to drive the disease process in MS. Teriflunomide may decrease the risk of infections compared to chemotherapy-like drugs because of its more-limited effects on the immune system.
Main symptoms of multiple sclerosis Symptoms and findings in multiple sclerosis. Multiple sclerosis can cause a variety of symptoms varying significantly in severity and progression among individuals: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty moving; difficulties with coordination and balance; problems in speech or swallowing (), visual ...
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease, MS disrupts the nervous system's ability to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
The most common side effects include rash, infusion-related reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection. [8] Mogamulizumab was approved for medical use in Japan in 2012. It was approved for medical use in the United States and the European Union in 2018.